remove_red_eye 518 Views
#Internal Medicine #Pharmacist #Pulmonary Medicine
An FDA advisory committee voted 10-7 that nintedanib (Ofev) should be approved to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Currently marketed to treat idiopathic pulmonary fibrosis (IPF), nintedanib would become the first drug approved for SSc-ILD, a condition with few other options for treatment.
The main data supporting the label expansion came from the phase III, double-blind, placebo-controlled SENSCIS trial involving some 580 patients across 32 countries… (Medpage Today)